Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever
Thomas J. Walsh(Cornell University), Jeanette Lee(National Institute of Allergy and Infectious Diseases), Patrick J. Stiff(Loyola University Medical Center), John Raffalli(New York Medical College), Robert W. Finberg(Dana-Farber Cancer Institute), Mindy G. Schuster(Unknown), John R. Perfect(Duke University), E. J. Anaissie, Gary Garber(University of Ottawa), Hillard M. Lazarus(University Hospitals of Cleveland), Susan Hadley(Tufts Medical Center), Gerald R. Donowitz(University of Virginia), Richard N. Greenberg(University of Alabama at Birmingham), Saul Yanovich(Virginia Commonwealth University Medical Center), Giuseppe Fioritoni, Annette C. Reboli(Cooper Medical School of Rowan University), Finn Bo Petersen(Intermountain Healthcare), John F. Reinhardt(New York Medical College), Peter G. Pappas(University of Alabama at Birmingham), Drew J. Winston(University of California, Los Angeles), John R. Wingard(University of Florida Health), Carola Arndt(Mayo Clinic), Michél Laverdière
Cited by 986
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2015|4k
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2009|3.2k
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
|Clinical Infectious Diseases|2005|3k